



**navalpro CR**  
sodium valproate | valproic acid

# The Black and White of Grey Matter

An affordable<sup>1</sup> sodium valproate  
for the treatment of bipolar disorder

#### IMPORTANT SAFETY INFORMATION

NAVALPRO is contraindicated in pregnancy and lactation. There have been reports of foetal abnormalities in women receiving valproate during pregnancy. NAVALPRO should not be used in women of childbearing potential.



Reference: 1. Medikredit manufacturing pricing report, 12 April 2020.

**NAVALPRO CR 200.** Reg. No.: 45/2.5/0411. Each film-coated controlled release tablet contains 133.2 mg sodium valproate and 58.0 mg valproic acid, together equivalent to 200 mg sodium valproate.  
**NAVALPRO CR 300.** Reg. No.: 45/2.5/0091. Each film-coated controlled release tablet contains 199.8 mg sodium valproate and 87.0 mg valproic acid, together equivalent to 300 mg sodium valproate.  
**NAVALPRO CR 500.** Reg. No.: 45/2.5/0092. Each film-coated controlled release tablet contains 333.0 mg sodium valproate and 145.0 mg valproic acid, together equivalent to 500 mg sodium valproate.

For full prescribing information refer to the professional information approved by the medicines regulatory authority (03/2013). **HCR:** Brimpharm SA (Pty) Ltd. (Reg. No.: 1998/021326/07). 215 Main Road, Claremont, 7708, Cape Town, South Africa. Trademarks are owned by or licensed to the Aspen Group of companies. © 2020 Aspen Group of companies or its licensor. All rights reserved. Marketed by Aspen. Healthcare Park, Woodlands Drive, Woodmead, 2191. ZAR-VA-09-20-00003 09/20 MENAV2024



*Healthcare. We Care.*

Marketed by Aspen Pharmacare  
[www.aspenpharma.com](http://www.aspenpharma.com)  
Medical Hotline 0800 118 088